DR. RAYMOND LEON WOOSLEY, MD, PHD
Osteopathic Medicine at Innovation Park Dr, Tucson, AZ
License number
Arizona 29774
Category
Osteopathic Medicine
Type
Clinical Pharmacology
Address
Address
1822 E Innovation Park Dr, Tucson, AZ 85755
Phone
(520) 989-0900
(520) 229-2191 (Fax)
(520) 229-2190
(520) 229-2191 (Fax)
(520) 229-2190
Personal information
See more information about RAYMOND LEON WOOSLEY at radaris.comName
Address
Phone
1457 E Desert Garden Dr, Tucson, AZ 85718
7984 N Pima Village Ct, Tucson, AZ 85718
1457 Desert Garden Dr, Tucson, AZ 85718
416 Fiesta Del Sol, Florence, AZ 85232
1457 E Desert Garden Dr, Tucson, AZ 85718
Professional information
See more information about RAYMOND LEON WOOSLEY at trustoria.com
President &Amp; Ceo At Critical Path Institute
President &Amp; Ceo At Critical Path Institute
Position:
President & CEO at Critical Path Institute
Location:
Tucson, Arizona Area
Industry:
Pharmaceuticals
Work:
Critical Path Institute
-
President & CEO
Dr. Raymond L Woosley, Oro Valley AZ - MD (Doctor of Medicine)
Dr. Raymond L Woosley, Oro Valley AZ - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
1822 E Innovation Park Dr, Oro Valley 85755
(520) 989-0900 (Phone), (520) 229-2191 (Fax)
(520) 989-0900 (Phone), (520) 229-2191 (Fax)
Certifications:
Internal Medicine, 1976
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Miami / School of Medicine
Graduated: 1973
Vanderbilt U Hosp
Vanderbilt University
University of Miami / School of Medicine
Graduated: 1973
Vanderbilt U Hosp
Vanderbilt University
Genetic Diagnosis For Qt Prolongation Related Adverse Drug Reactions
Genetic Diagnosis For Qt Prolongation Related Adverse Drug Reactions
US Patent:
7179597, Feb 20, 2007
Filed:
Apr 13, 2001
Appl. No.:
10/257573
Inventors:
Raymond L. Woosley - Tucson AZ, US
Assignee:
Georgetown University - Washington DC
International Classification:
C12Q 1/68, C12N 15/11, C12N 15/12
US Classification:
435 6, 536 232, 536 235, 536 231, 536 2431
Abstract:
The specification is directed to a method of diagnosing whether a subject is predisposed to an adverse reaction to one or more pharmaceutical agents which may induce a prolonged QT interval or acquired LQTS in that individual. The diagnosis is genetic analysis of at least two polymorphisms or mutations which the individual may have, which are associated with an increased risk for prolonged QT intervals or Torsades de Pointes (TdP). Genetic screening for determining the predisposition of prolonged QT intervals induced by a pharmaceutical agent is performed by identifying genetic polymorphisms or mutations located in at least two classes of genes, wherein the genes are (1) LQT genes, (2) altered sensitivity genes (e. g. , MiRP1) or (3) increased exposure genes (e. g. , MDR genes or P450 cytochrome genes).
Method For Evaluating A Diagnostic Test
Method For Evaluating A Diagnostic Test
US Patent:
2009009, Apr 9, 2009
Filed:
Oct 9, 2008
Appl. No.:
12/248560
Inventors:
Raymond Woosley - Tucson AZ, US
Jeffrey Cossman - Potomac MD, US
Jeffrey Cossman - Potomac MD, US
International Classification:
G21C 17/00
US Classification:
702182
Abstract:
One aspect of the present invention generally relates to a method for standardizing and evaluating a diagnostic test. The method includes generating at least one of a standard, control, or sample required for a validation. Then, the at least one of a standard, control, or sample is compared to at least one of an assay, protocol, or reagent for testing on a predetermined number of aspects of performance. Finally, an indicator that represents the performance of the diagnostic test. Preferably, the method is performed at a centralized location on a plurality of diagnostic tests.